<DOC>
	<DOCNO>NCT00373451</DOCNO>
	<brief_summary>The purpose study determine anti-clotting medication , abciximab plus unfractionated heparin bivalirudin , effective prevent thrombotic bleeding complication patient suffer heart attack undergo coronary intervention .</brief_summary>
	<brief_title>Randomized Comparison Abciximab Plus Heparin With Bivalirudin Acute Coronary Syndrome</brief_title>
	<detailed_description>Non-ST elevation myocardial infarction ( NSTEMI ) associate increase risk death major reason hospital admission . Most frequently , sequence event lead NSTEMI characterize disrupt atherosclerotic plaque , platelet activation aggregation , thrombus formation microembolizations . Patients NSTEMI treat early invasive strategy intensive work progress define optimal antithrombotic therapy use adjunct percutaneous coronary intervention ( PCI ) patient . Bivalirudin , direct thrombin inhibitor , glycoprotein IIb/IIIa inhibitor ( GPI ) abciximab focus recent trial patient acute coronary syndrome ( ACS ) . In recent randomize , open-label trial ( ACUITY trial ) , patient suspicion ACS basis type anginal symptom , ST-segment displacement , elevate biomarkers several risk indicator randomize receive bivalirudin alone bail-out GPIs , bivalirudin plus GPIs , heparin/low-molecular weight heparin plus GPI . The GPIs frequently use eptifibatide tirofiban . Abciximab give &lt; 9 % case . In another randomize , double-blind , placebo-controlled trial ( ISAR-REACT-2 ) include ACS patient undergo PCI , abciximab administer cath lab associate significant reduction ischemic event patient NSTEMI , lead measurable increase major bleed complication . However , know whether abciximab also superior bivalirudin patient NSTEMI . We design study ass whether abciximab add unfractionated heparin superior bivalirudin patient NSTEMI .</detailed_description>
	<mesh_term>Infarction</mesh_term>
	<mesh_term>Myocardial Infarction</mesh_term>
	<mesh_term>Coronary Disease</mesh_term>
	<mesh_term>Coronary Artery Disease</mesh_term>
	<mesh_term>Calcium heparin</mesh_term>
	<mesh_term>Abciximab</mesh_term>
	<mesh_term>Bivalirudin</mesh_term>
	<mesh_term>Heparin</mesh_term>
	<mesh_term>Hirudins</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<mesh_term>Immunoglobulin Fab Fragments</mesh_term>
	<criteria>Episode unstable angina Elevated cardiac marker Angiographic lesion require PCI Informed , write consent Age &lt; 18 year &gt; 80 year STsegment elevation acute myocardial infarction within 48 hour Cardiogenic shock Pericarditis Malignancies comorbid condition life expectancy le one year may result protocol noncompliance Active bleeding ; bleed diathesis ; history gastrointestinal genitourinary bleeding , recent trauma major surgery last month ; history intracranial bleed structural abnormality ; suspect aortic dissection ; pericarditis ; patient 's refusal blood transfusion Oral anticoagulation therapy coumarin derivative within last 7 day Recent use GPIIb/IIIa inhibitor within 14 day Treatment unfractionated heparin within 4 hour unless ACT &gt; 150sec ; lowmolecular weight heparin within 8 hour randomization Treatment bivalirudin within 24 hour randomization Severe uncontrolled hypertension &gt; 180/110 mm Hg unresponsive therapy Planned stag PCI procedure within 30 day index procedure prior PCI within last 30 day Relevant hematologic deviation Glomerular filtration rate ( GFR ) &lt; 30 ml/min serum creatinine &gt; 30 mg/L dependence renal dialysis Known allergy intolerance study medication , stainless steel true anaphylaxis prior exposure contrast medium Previous enrollment trial Women know pregnant , childbearing potential test positive pregnancy , give birth within last 90 day , breastfeed Patient 's inability fully cooperate study protocol</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>May 2012</verification_date>
	<keyword>NSTEMI</keyword>
</DOC>